O	0	7	Heparin	Heparin	NN	B-NP
O	8	19	immobilized	immobilize	VBD	B-VP
O	20	26	porous	porous	JJ	B-NP
O	27	31	PLGA	PLGA	NN	I-NP
O	32	44	microspheres	microsphere	NNS	I-NP
O	45	48	for	for	IN	B-PP
O	49	59	angiogenic	angiogenic	JJ	B-NP
O	60	66	growth	growth	NN	I-NP
O	67	73	factor	factor	NN	I-NP
O	74	82	delivery	delivery	NN	I-NP
O	82	83	.	.	.	O

O	84	91	PURPOSE	PURPOSE	NN	B-NP
O	91	92	:	:	:	O
O	93	100	Heparin	Heparin	NN	B-NP
O	101	112	immobilized	immobilize	VBD	B-VP
O	113	119	porous	porous	JJ	B-NP
O	120	124	poly	poly	NN	I-NP
O	124	125	(	(	(	O
O	125	126	D	D	NN	B-NP
O	126	127	,	,	,	O
O	127	128	L	L	NN	B-NP
O	128	129	-	-	HYPH	B-VP
O	129	135	lactic	lactic	JJ	B-ADJP
O	135	136	-	-	HYPH	O
O	136	138	co	co	AFX	O
O	138	139	-	-	HYPH	O
O	139	147	glycolic	glycolic	JJ	B-NP
O	148	152	acid	acid	NN	I-NP
O	152	153	)	)	)	O
O	154	155	(	(	(	O
O	155	159	PLGA	PLGA	NN	B-NP
O	159	160	)	)	)	O
O	161	173	microspheres	microsphere	NNS	B-NP
O	174	178	were	be	VBD	B-VP
O	179	187	prepared	prepare	VBN	I-VP
O	188	191	for	for	IN	B-PP
O	192	201	sustained	sustained	JJ	B-NP
O	202	209	release	release	NN	I-NP
O	210	212	of	of	IN	B-PP
O	213	218	basic	basic	JJ	B-NP
O	219	229	fibroblast	fibroblast	NN	I-NP
O	230	236	growth	growth	NN	I-NP
O	237	243	factor	factor	NN	I-NP
O	244	245	(	(	(	O
O	245	249	bFGF	bFGF	NN	B-NP
O	249	250	)	)	)	O
O	251	253	to	to	TO	B-VP
O	254	260	induce	induce	VB	I-VP
O	261	273	angiogenesis	angiogenesis	NN	B-NP
O	273	274	.	.	.	O

O	275	284	MATERIALS	MATERIALS	NNS	B-NP
O	285	288	AND	AND	CC	I-NP
O	289	296	METHODS	METHODS	NNS	I-NP
O	296	297	:	:	:	O
O	298	304	Porous	Porous	JJ	B-NP
O	305	309	PLGA	PLGA	NN	I-NP
O	310	322	microspheres	microsphere	NNS	I-NP
O	323	329	having	have	VBG	B-VP
O	330	337	primary	primary	JJ	B-NP
O	338	343	amine	amine	NN	I-NP
O	344	350	groups	group	NNS	I-NP
O	351	353	on	on	IN	B-PP
O	354	357	the	the	DT	B-NP
O	358	365	surface	surface	NN	I-NP
O	366	370	were	be	VBD	B-VP
O	371	379	prepared	prepare	VBN	I-VP
O	380	385	using	use	VBG	B-VP
O	386	388	an	an	DT	B-NP
O	389	392	oil	oil	NN	I-NP
O	392	393	-	-	HYPH	B-ADJP
O	393	395	in	in	IN	B-PP
O	395	396	-	-	HYPH	B-NP
O	396	401	water	water	NN	I-NP
O	402	403	(	(	(	O
O	403	404	O	O	NN	B-NP
O	404	405	/	/	SYM	B-NP
O	405	406	W	W	NN	I-NP
O	406	407	)	)	)	I-NP
O	408	414	single	single	JJ	I-NP
O	415	423	emulsion	emulsion	NN	I-NP
O	424	430	method	method	NN	I-NP
O	431	436	using	use	VBG	B-VP
O	437	445	Pluronic	Pluronic	JJ	B-NP
O	446	447	F	F	NN	I-NP
O	447	448	-	-	HYPH	O
O	448	451	127	127	CD	B-NP
O	452	454	as	as	IN	B-PP
O	455	457	an	an	DT	B-NP
O	458	469	extractable	extractable	JJ	I-NP
O	470	477	porogen	porogen	NN	I-NP
O	477	478	.	.	.	O

O	479	486	Heparin	Heparin	NN	B-NP
O	487	490	was	be	VBD	B-VP
O	491	498	surface	surface	NN	B-NP
O	499	510	immobilized	immobilize	VBN	B-VP
O	511	514	via	via	IN	B-PP
O	515	523	covalent	covalent	JJ	B-NP
O	524	535	conjugation	conjugation	NN	I-NP
O	535	536	.	.	.	O

O	537	541	bFGF	bFGF	NN	B-NP
O	542	545	was	be	VBD	B-VP
O	546	552	loaded	load	VBN	I-VP
O	553	557	into	into	IN	B-PP
O	558	561	the	the	DT	B-NP
O	562	569	heparin	heparin	NN	I-NP
O	570	584	functionalized	functionalize	VBD	B-VP
O	585	586	(	(	(	O
O	586	590	PLGA	PLGA	NN	B-NP
O	590	591	-	-	HYPH	B-NP
O	591	598	heparin	heparin	NN	I-NP
O	598	599	)	)	)	O
O	600	612	microspheres	microsphere	NNS	B-NP
O	613	615	by	by	IN	B-PP
O	616	617	a	a	DT	B-NP
O	618	624	simple	simple	JJ	I-NP
O	625	632	dipping	dipping	NN	I-NP
O	633	639	method	method	NN	I-NP
O	639	640	.	.	.	O

O	641	644	The	The	DT	B-NP
O	645	649	bFGF	bFGF	NN	I-NP
O	650	656	loaded	load	VBD	B-VP
O	657	661	PLGA	PLGA	NN	B-NP
O	661	662	-	-	HYPH	B-NP
O	662	669	heparin	heparin	NN	I-NP
O	670	682	microspheres	microsphere	NNS	I-NP
O	683	687	were	be	VBD	B-VP
O	688	694	tested	test	VBN	I-VP
O	695	698	for	for	IN	B-PP
O	699	701	in	in	FW	B-NP
O	702	707	vitro	vitro	FW	I-NP
O	708	715	release	release	NN	I-NP
O	716	719	and	and	CC	O
O	720	722	in	in	FW	B-NP
O	723	727	vivo	vivo	FW	I-NP
O	728	738	angiogenic	angiogenic	JJ	I-NP
O	739	747	activity	activity	NN	I-NP
O	747	748	.	.	.	O

O	749	756	RESULTS	RESULTS	NNS	B-NP
O	756	757	:	:	:	O
O	758	762	PLGA	PLGA	NN	B-NP
O	763	775	microspheres	microsphere	NNS	I-NP
O	776	780	with	with	IN	B-PP
O	781	783	an	an	DT	B-NP
O	784	788	open	open	JJ	I-NP
O	788	789	-	-	HYPH	I-NP
O	789	795	porous	porous	JJ	I-NP
O	796	805	structure	structure	NN	I-NP
O	806	810	were	be	VBD	B-VP
O	811	817	formed	form	VBN	I-VP
O	817	818	.	.	.	O

O	819	822	The	The	DT	B-NP
O	823	829	amount	amount	NN	I-NP
O	830	832	of	of	IN	B-PP
O	833	843	conjugated	conjugate	VBN	B-NP
O	844	849	amine	amine	NN	I-NP
O	850	855	group	group	NN	I-NP
O	856	860	onto	onto	IN	B-PP
O	861	864	the	the	DT	B-NP
O	865	877	microspheres	microsphere	NNS	I-NP
O	878	881	was	be	VBD	B-VP
O	882	883	1	1	CD	B-NP
O	883	884	.	.	.	I-NP
O	884	886	93	93	CD	I-NP
O	886	887	+	+	SYM	O
O	887	888	/	/	SYM	O
O	888	889	-	-	SYM	B-NP
O	889	890	0	0	CD	B-NP
O	890	891	.	.	SYM	I-NP
O	891	893	01	01	CD	I-NP
O	894	898	nmol	nmol	NN	I-NP
O	898	899	/	/	SYM	B-NP
O	899	901	mg	mg	NN	I-NP
O	901	902	-	-	HYPH	B-NP
O	902	914	microspheres	microsphere	NNS	I-NP
O	914	915	,	,	,	O
O	916	921	while	while	IN	B-SBAR
O	922	925	the	the	DT	B-NP
O	926	932	amount	amount	NN	I-NP
O	933	935	of	of	IN	B-PP
O	936	943	heparin	heparin	NN	B-NP
O	944	947	was	be	VBD	B-VP
O	948	950	95	95	CD	B-NP
O	950	951	.	.	.	O
O	951	952	8	8	CD	B-NP
O	953	957	pmol	pmol	NN	I-NP
O	957	958	/	/	SYM	B-NP
O	958	960	mg	mg	NN	I-NP
O	960	961	-	-	HYPH	B-NP
O	961	973	microspheres	microsphere	NNS	I-NP
O	973	974	.	.	.	O

O	975	979	PLGA	PLGA	NN	B-NP
O	979	980	-	-	HYPH	I-NP
O	980	987	heparin	heparin	NN	I-NP
O	988	1000	microspheres	microsphere	NNS	I-NP
O	1001	1009	released	release	VBN	B-VP
O	1010	1013	out	out	RP	B-PRT
O	1014	1018	bFGF	bFGF	NN	B-NP
O	1019	1021	in	in	IN	B-PP
O	1022	1023	a	a	DT	B-NP
O	1024	1028	more	more	RBR	I-NP
O	1029	1038	sustained	sustained	JJ	I-NP
O	1039	1045	manner	manner	NN	I-NP
O	1046	1050	with	with	IN	B-PP
O	1051	1052	a	a	DT	B-NP
O	1053	1060	smaller	small	JJR	I-NP
O	1061	1067	extent	extent	NN	I-NP
O	1068	1070	of	of	IN	B-PP
O	1071	1078	initial	initial	JJ	B-NP
O	1079	1084	burst	burst	NN	I-NP
O	1085	1089	than	than	IN	B-PP
O	1090	1094	PLGA	PLGA	NN	B-NP
O	1095	1107	microspheres	microsphere	NNS	I-NP
O	1107	1108	,	,	,	O
O	1109	1119	indicating	indicate	VBG	B-VP
O	1120	1124	that	that	IN	B-SBAR
O	1125	1132	surface	surface	NN	B-NP
O	1133	1144	immobilized	immobilize	VBN	I-NP
O	1145	1152	heparin	heparin	NN	I-NP
O	1153	1163	controlled	control	VBD	B-VP
O	1164	1167	the	the	DT	B-NP
O	1168	1175	release	release	NN	I-NP
O	1176	1180	rate	rate	NN	I-NP
O	1181	1183	of	of	IN	B-PP
O	1184	1188	bFGF	bFGF	NN	B-NP
O	1188	1189	.	.	.	O

B-Immaterial_anatomical_entity	1190	1202	Subcutaneous	Subcutaneous	JJ	B-NP
O	1203	1215	implantation	implantation	NN	I-NP
O	1216	1218	of	of	IN	B-PP
O	1219	1223	bFGF	bFGF	NN	B-NP
O	1224	1230	loaded	load	VBD	B-VP
O	1231	1235	PLGA	PLGA	NN	B-NP
O	1235	1236	-	-	HYPH	B-NP
O	1236	1243	heparin	heparin	NN	I-NP
O	1244	1256	microspheres	microsphere	NNS	I-NP
O	1257	1259	in	in	IN	B-PP
O	1260	1264	mice	mouse	NNS	B-NP
O	1265	1278	significantly	significantly	RB	B-ADVP
O	1279	1286	induced	induce	VBD	B-VP
O	1287	1290	the	the	DT	B-NP
O	1291	1300	formation	formation	NN	I-NP
O	1301	1303	of	of	IN	B-PP
O	1304	1307	new	new	JJ	B-NP
B-Tissue	1308	1316	vascular	vascular	JJ	I-NP
I-Tissue	1317	1329	microvessels	microvessel	NNS	I-NP
O	1329	1330	.	.	.	O

O	1331	1342	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1342	1343	:	:	:	O
O	1344	1348	PLGA	PLGA	NN	B-NP
O	1349	1361	microspheres	microsphere	NNS	I-NP
O	1362	1366	with	with	IN	B-PP
O	1367	1369	an	an	DT	B-NP
O	1370	1374	open	open	JJ	I-NP
O	1375	1381	porous	porous	JJ	I-NP
O	1382	1391	structure	structure	NN	I-NP
O	1392	1399	allowed	allow	VBD	B-VP
O	1400	1411	significant	significant	JJ	B-NP
O	1412	1418	amount	amount	NN	I-NP
O	1419	1421	of	of	IN	B-PP
O	1422	1429	heparin	heparin	NN	B-NP
O	1430	1444	immobilization	immobilization	NN	I-NP
O	1445	1448	and	and	CC	O
O	1449	1453	bFGF	bFGF	NN	B-NP
O	1454	1461	loading	loading	NN	I-NP
O	1461	1462	.	.	.	O

O	1463	1467	bFGF	bFGF	NN	B-NP
O	1468	1474	loaded	load	VBD	B-VP
O	1475	1479	PLGA	PLGA	NN	B-NP
O	1479	1480	-	-	HYPH	B-NP
O	1480	1482	HP	HP	NN	I-NP
O	1483	1495	microspheres	microsphere	NNS	I-NP
O	1496	1502	showed	show	VBD	B-VP
O	1503	1512	sustained	sustained	JJ	B-NP
O	1513	1520	release	release	NN	I-NP
O	1521	1529	profiles	profile	NNS	I-NP
O	1530	1532	of	of	IN	B-PP
O	1533	1537	bFGF	bFGF	NN	B-NP
O	1538	1540	in	in	FW	B-ADVP
O	1541	1546	vitro	vitro	FW	I-ADVP
O	1546	1547	,	,	,	O
O	1548	1561	demonstrating	demonstrate	VBG	B-VP
O	1562	1572	reversible	reversible	JJ	B-NP
O	1573	1576	and	and	CC	I-NP
O	1577	1585	specific	specific	JJ	I-NP
O	1586	1593	binding	binding	NN	I-NP
O	1594	1596	of	of	IN	B-PP
O	1597	1601	bFGF	bFGF	NN	B-NP
O	1602	1604	to	to	TO	B-PP
O	1605	1616	immobilized	immobilize	VBN	B-NP
O	1617	1624	heparin	heparin	NN	I-NP
O	1624	1625	.	.	.	O

O	1626	1630	They	They	PRP	B-NP
O	1631	1635	also	also	RB	B-ADVP
O	1636	1643	induced	induce	VBD	B-VP
O	1644	1649	local	local	JJ	B-NP
O	1650	1662	angiogenesis	angiogenesis	NN	I-NP
O	1663	1665	in	in	FW	B-ADVP
O	1666	1670	vivo	vivo	FW	I-ADVP
O	1671	1673	in	in	IN	B-PP
O	1674	1676	an	an	DT	B-NP
O	1677	1683	animal	animal	NN	I-NP
O	1684	1689	model	model	NN	I-NP
O	1689	1690	.	.	.	O

